Dominant-negative proteins

Inhibition of clathrin function can be achieved by different approaches (Table 1). Here, we describe the most commonly used inhibitory drugs and the newer and more specific molecular inhibitors in the form of dominant negative proteins. 

Two independent kindreds with insulin-resistant type 2 diabetes in association with novel PPARy mutations were recently described (64). In both cases, the mutations—Val—>Met290 and Pro—>Leu467—were shown to function as dominant-negative proteins when expressed in transfected cells. This compelling story provides further proof of the role of PPARy as a potential regulator of in vivo insulin action. 

Nuclear export of unspliced RNA RevMlO Transdominant HIV Rev protein Dominant negative Sam68, a Rev homolog scFv to Rev RRE decoy HIV-1 Habu et al. 2005 Hotchkiss et al. 2004 Li et al. 1998a, b Yamada et al. 1994... 

Townsley, F. M., Aristarkhov, A., Beck, S., Hershko, A., and Ruderman, J. V. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc. Natl. Acad. Sei. USA 1997, 94, 2362-67. 

---